Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. (October 2021)

• Record Type: Journal Article
• Authors: Schönfelder, Kristina; Schuh, Helene; Pfister, Frederick; Krämer, Julia; Eisenberger, Ute; Skuljec, Jelena; Hackert, Jana; Ruck, Tobias; Pfeuffer, Steffen; Fleischer, Michael; Gäckler, Anja; Hagenacker, Tim; Kribben, Andreas; Meuth, Sven G; Kleinschnitz, Christoph; Pul, Refik
• Is Part Of: Multiple sclerosis. Volume 27:Number 12(2021)
• Page Start: 1960
• Page End: 1964
• Publication Date: 2021-10
• Subjects: Relapsing multiple sclerosis -- cladribine tablets -- adverse event -- secondary autoimmunity -- anti-glomerular basement membrane antibodies -- thrombocytopenia -- autoimmune hepatitis; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585211022719
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. Objective and Results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle. Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.